Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.

Ghigo E, Gianotti L, Arvat E, Ramunni J, Valetto MR, Broglio F, Rolla M, Cavagnini F, Müller EE

The Journal of clinical endocrinology and metabolism1 Jan 1999Cited by 26 (Europe PMC)

PMID9920097DOI10.1210/jcem.84.1.5386PepBankPUB-09920097

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialEfficacy outcome
In healthy young women, the GH response to hexarelin alone was higher than that to GHRH alone.
In plain wordsIn healthy young women, hexarelin raised growth hormone more than GHRH did.
Peptide
Hexarelin
Outcome
IncreaseGH response to hexarelin versus GHRH
Study
n = 8
Comparator
GHRH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2.0 microg/kg · intravenousAs given in this study (human).
Source sentences
Summary
In fact, the GH response to GHRH alone was clearly lower than that to HEX alone (P < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of rhIGF-I administration (20 microg/kg s.c. at 0 min) on GH secretion, either spontaneous or stimulated by GHRH (2 microg/kg i.v. at +180 min) or Hexarelin (HEX, 2.0 microg/kg i.v at +180 min), a GHS, in eight normal young women
Report a problemFND-0992009703

Studies that did not test the peptide alone3

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

02HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In healthy young women, rhIGF-I administration inhibited the GH response to hexarelin.
In plain wordsIn healthy young women, IGF-I lowered the growth hormone response to hexarelin.
Peptide
Hexarelin
Outcome
DecreaseGH response to hexarelin after rhIGF-I
Study
n = 8
Comparator
hexarelin alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC(180-300 min)
620.3 microg/L x h
hexarelin after rhIGF-I
GH AUC(180-300 min)
1705.9 microg/L x h
hexarelin alone
Source sentences
Summary
whereas it inhibited the GH response to both GHRH (AUC(180-300 min) 447.7 +/- 159.4 vs. 715.9 +/- 104.3 microg/L x h, P < 0.05) and HEX (620.3 +/- 110.4 vs. 1705.9 +/- 328.9 microg/L x h, P < 0.03)
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of rhIGF-I administration (20 microg/kg s.c. at 0 min) on GH secretion, either spontaneous or stimulated by GHRH (2 microg/kg i.v. at +180 min) or Hexarelin (HEX, 2.0 microg/kg i.v at +180 min), a GHS, in eight normal young women
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0992009701
03HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In healthy young women, rhIGF-I inhibited the GH response to hexarelin by 57.7% and the response to GHRH by 41.7%.
In plain wordsIn healthy young women, IGF-I reduced the growth hormone response to hexarelin by 57.7% and to GHRH by 41.7%.
Peptide
Hexarelin
Outcome
DecreasePercent inhibition by rhIGF-I of the GH response
Study
n = 8
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Inhibition of GH response
57.7%
hexarelin
Inhibition of GH response
41.7%
GHRH
Source sentences
Summary
The percent inhibitory effect of rhIGF-I on the GH response to GHRH (41.7 +/- 12.8%) was lower than that on the response to HEX (57.7 +/- 11.0%).
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of rhIGF-I administration (20 microg/kg s.c. at 0 min) on GH secretion, either spontaneous or stimulated by GHRH (2 microg/kg i.v. at +180 min) or Hexarelin (HEX, 2.0 microg/kg i.v at +180 min), a GHS, in eight normal young women
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0992009702
04HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In healthy young women given rhIGF-I, the GH responses to hexarelin and GHRH were similar.
In plain wordsIn healthy young women given IGF-I, growth hormone responses to hexarelin and GHRH were similar.
Peptide
Hexarelin
Outcome
No significant changeGH responses to hexarelin and GHRH after rhIGF-I
Study
n = 8
Comparator
GHRH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
whereas the GH responses to GHRH and HEXwere similar after rhIGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of rhIGF-I administration (20 microg/kg s.c. at 0 min) on GH secretion, either spontaneous or stimulated by GHRH (2 microg/kg i.v. at +180 min) or Hexarelin (HEX, 2.0 microg/kg i.v at +180 min), a GHS, in eight normal young women
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0992009704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
14 Oct 2026, 01:46 UTC
Study data updated · source update from Europe PMC
Version 2
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.

Summary

Results from this study4

Studies that did not test the peptide alone3

Version history

Subjects

Publication types

MeSH terms